Kate Excoffon
American Society for Gene and Cell Therapy, American Society of Gene & Cell Therapy
Kate Excoffon is listed as American Society for Gene and Cell Therapy, American Society of Gene & Cell Therapy. Kate is scheduled to speak at Advanced Therapies Week 2027 on 19 January 2027.
Compiled from published conference agendas; not yet confirmed by Kate. Is this you? Claim this profile.
About
Kate Excoffon, PhD, is CEO and Founder of Gene Tx Optimized LLC and Chair of the ASGCT Bio-Industry Committee (2025–27). Her 30-year career in AAV, adenovirus, and lentiviral gene therapy spans discovery through first-in-human dosing. Her PhD work at the University of British Columbia was foundational to Glybera, the first gene therapy approved in the Western world; as a postdoc and scientist at the University of Iowa she discovered the airway-tropic capsid AAV2.5T by directed evolution (PNAS 2009); as VP of Research at Spirovant Sciences she led that capsid from preclinical proof-of-concept through IND to first-in-human dosing as SP-101 for cystic fibrosis in 2024. Formerly Full Professor at Wright State University. 50+ publications, three patents. Gene Tx Optimized is a senior advisory practice — CMC, translational science, and IND/CTA strategy to FIH — and a home for the venture-stage biotech programs Kate is building.
Upcoming
Advanced Therapies Week 2027 19 January 2027 – 21 January 2027
- Panel discussion: What is the data telling us about the clinical pathway to safe and efficacious in vivo gene therapy products? Speaker · 19 January 2027
- Session 1: How are key gene delivery platforms stacking up both in vivo and ex vivo to address concerns around safety, immunogenicity, durability, efficacy, and redosing potential? Speaker · 19 January 2027
- Panel: Integrating new approach methodologies into early development: Where do NAMs deliver the greatest value? Speaker · 20 January 2027
- Session 4: How and where to harness NAMs in support of in vivo preclinical models in practice? Learning lessons from recent regulatory responses to IND applications Speaker · 20 January 2027
Spoke alongside
People who have shared a session with Kate at events on B2DB.
- Mark Kay Dennis Farrey Family Professor, Departments of Pediatrics and Genetics; Head, Division of Human Gene Therapy · Stanford University 2 shared sessions
- Mercedes Segura Gally VP Process Development · Editas Medicine 2 shared sessions
- Vivian Choi Vice President, Liver Programs and Nonclinical Development · Prime Medicine, Inc. 1 shared session